Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.
132441
Pulmatrix launches iSPERSE, a novel inhaled dry powder drug delivery platform
137637
Merichem introduces innovation for removing mercaptan odors from
42745
Pehla introduces new technology
165359
Valsecchi signs on with iSport
107899
First effective treatment for most common form of Hepatitis C launched
108482
Regulatory, commercial considerations are the primary drivers for biosimilar development
57802
Pepscan achieves a breakthrough with CLIPS immunogen technology:
117198
Sopra Group announces a plan of
66180
Researchers to begin drug development projects for rare and neglected diseases
28106
Incyte says psoriasis drug meets main goal
47238
MedNest incorporates and launches PharmaNest
102829
Encana to speed up commercialization of liquids-rich assets
139618
SurModics's subsidiary licenses nanoparticle technology from PharmaSol
123993
FDA approves new drug for multiple sclerosis
164192
Iscopia announces the launch of the AQS(tm) service suite
107414
New breathing device may help high blood pressure
59485
Consortium supports next generation drug discovery